Dimension Therapeutics: Silence Therapeutics announces appointment of Dimension Therapeutics CEO as its non-executive chair

Silence Therapeutics PLC (LON:SLN) has announced the appointment of Dr Annalisa Jenkins, CEO of Dimension Therapeutics Inc. (NASDAQ:DMTX) as the AIM-listed group's non-executive chair with effect from today. Jenkins will succeed Dr. Stephen Parker, the company's non-executive chairman since September 2015 who will become a non-executive director. READ: Silence Therapeutics believes a number of drug developers may need to licence its technology following US patent grant Silence - a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need - pointed out that Jenkins brings over 25 years of global industry experience to its board, having held multiple leadership positions, including executive vice president, head of Global Research and Development for Merck Serono. In addition to her current and past directorships, Jenkins is also a committee member of the Science Board to the US Food & Drug Administration, serves on the advisory board of the Center for Talent Innovation (UK) and is on the Advisory Panel of the Healthcare Businesswomen's Association. Ali Mortazavi, chief executive officer of Silence, said: "Annalisa's appointment is a significant moment in the transition of Silence to a fully-integrated biopharma company. Her extensive and broad experience in all aspects of biotechnology, drug development and commercialization will prove to be invaluable." He added: "It is a testament to the progress made at Silence that we have been able to attract Annalisa to our Board. Her appointment is a signal of our continued belief that 2017 will be remembered as "the year of RNAi."